Side Effects of Xofigo – Are They Significant?

The following post is actually a response to a listserve issue over the side effects of Xofigo. I decided to post my response here to avoid the limit of lines allowed on the listserve and because I feel that it is also of interest to my regular readers of this blog. My response is using [...]

Short Video Explaining Xofigo (Radium 223 Dichloride, Alpharadin or Radium 223)

The New England Journal of Medicine just published a very appealing and easy to understand video about Xofigo dichloride (Radium 223 or Alpharadin), the newly FDA approved treatment for men with advanced prostate cancer who have developed bone metastasis. The short video can be viewed at: N.E. Journal Xofigo Video Joel T. Nowak, M.A., M.S.W.

Radium-223, An Alpha Emitter Treatment for Advanced Prostate Cancer Called A Breakthrough Treatment

In an interview about radium 223 with Medscape Medical News, Dr. Vapiwala pointed out that radium-223 is the first alpha-emitter to reach the market, and described it as a "breakthrough for radiopharmaceuticals" and "another breakthrough for prostate cancer," as it joins several other agents that have recently been approved for this disease. She characterized the [...]

Increasing Cost of Treating Men with Advanced Prostate Cancer & Its Effects on the Payers

The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]

What is the Current Role of Taxanes in the Treatment of Metastatic Prostate Cancer?

Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]

Hopefully A Good Re-Start from Bayer Healthcare in Mending Their Ways & Building Trust with the Prostate Cancer Community

I want to share that I am hopeful that we have made progress with Bayer Healthcare and the issues I have written about surrounding the newly approved treatment for men with castrate resistant prostate cancer, Xofigo. I have shared that they failed to support the early access trials because of what they claimed were supply [...]

Ra 223 Dichloride (Xofigo®) Approved by the FDA

More great news for men with advanced prostate cancer that is castrate resistant and who also have symptomatic bone metastases and no known visceral metastatic disease. Today, Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved (radium Ra 223 dichloride). Xofigo (zo-FEE-go) is the first and only alpha particle-emitting radioactive therapeutic [...]

Go to Top